Cardiology

Short and long nighttime sleep duration, along with daytime napping, were associated with a moderate increase in risk of cardiovascular diseases.

Dr. Thosani discusses the convergence of technology and physiology, treatment advancements, and virtual medicine capabilities in the field of heart arrhythmia.

A reduction in aspirin use was associated with significantly less bleeding and health care use, without an increase in thrombotic outcomes.

High CPAP adherence also resulted in a significant protective effect on the 30-day readmission for beneficiaries with heart failure.

Announced on September 15 by Edwards Lifesciences Corporation, the PASCAL Precision transcatheter valve repair system has received approval for transcatheter edge-to-edge repair in patients with degenerative mitral regurgitation.

In this episode of Don’t Miss a Beat, hosts Stephen Greene, MD, and Muthiah Vaduganathan, MD, MPH, provide a recap of the European Society of Cardiology Congress 2022. This recap begins with a discussion on the results of the phase 3 DELIVER trial, in which Vaduganathan served as an investigator, the ADVOR trial, and REVIVED.

Short-term treatment with rosuvastatin was not linked to changes in insulin resistance markers in a cohort of children with familial hypercholesterolemia.

On September 1, Bayer announced the US FDA had approved a label update for finerenone (Kerendia), which received initial approval in July 2021 for chronic kidney disease associated with type 2 diabetes, to include cardiovascular outcomes data from the FIGARO-DKD trial.

These reductions were only observed in short-term follow-up and were driven by early reductions within 12 months of telemedicine intervention.

An analysis of the NutriNet-Santé cohort provides insight into the apparent increase in cardiovascular disease risk associated with consumption of artificial sweeteners.

A study presented at EASD 22 comparing 600k patients with type 2 diabetes against 1.2 million controls suggests a diagnosis of T2D prior to turning 40 was associated with a more than 5-fold increase in risk of mortality, heart failure hospitalization, and coronary heart disease.

Young adults with a high cumulative alcohol burden had up to 25% higher risk of incident AF.

A new study from the AHA's Hypertension Scientific Sessions provides an overview of the potential population-level benefit of behavior modification, including adherence to a DASH diet, on CVD events and mortality among patients with stage 1 hypertension.

The mean LDL-C level among US young adults was 104.9 mg/dL In 2015-2020.

Announced by Boston Scientific on September 6, the label for the WATCHMAN FLX LAAC device now includes a 45-day DAPT option as an alternative to the 45-day postprocedural OAC plus aspirin regimen for patients with nonvalvular atrial fibrillation.

In this podcast episode, Jorge Plutzky, MD, and Michael Farkouh, MD, speak with University of Maryland's Matthew Weir, MD, about the growing involvement of renal care in modern heart disease patients.

Our latest cardiology case report from Brady Pregerson, MD, features a man in his mid-50s presenting to the hospital with leg swelling that started 4 days ago but denies chest pain, SOB or other complaints. Check out the ECG and determine the correct diagnosis.

Mean systolic blood pressure increased by 5.09 mm Hg immediately after implementation of automated monitoring.

In the first episode of our monthly series, cardiologists Jorge Plutzky, MD, and Michael Farkouh, MD, interview nephrologist Matthew Weir, MD.

In his most recent column, Dr. Gregory Weiss provides perspective on recent data elucidating the links between insulin sensitivity, central adiposity, and atherosclerosis.

In his most recent column, Dr. Gregory Weiss provides an overview of a recent American College of Cardiology report detailing apparent increases in cardiovascular risk observed among pregnant women infected with COVID-19.

Serum total cholesterol, HDL-C, and LDL-C were associated positively with IOP, while triglyceride levels may be associated negatively.

The strongest risk factor for RVO was identified as nonideal blood pressure, followed by nonideal body mass index.

In a pivotal trial presented at ESC Congress 2022, Medtronic's investigational external ICD achieved a defibrillation success rate of 98.7% and met its safety endpoints in a global pivotal trial.

A lower SPPB score was associated with greater risk of composite and individual CVD outcomes.